The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Amoxicillin for Oral Suspension USP, the Hyderabad-based firm said in a statement.
Amoxicillin for Oral Suspension is the generic equivalent to the Teva Pharmaceutical Industries' product and indicated in the treatment of infections, it added.
According to IMS sales data, the product has a market size of around USD 19 million for the 12 months ended July 2014.
Aurobindo now has a total of 195 ANDA approvals from the USFDA.
Shares of Aurobindo Pharma today closed at Rs 854.30 apiece on the BSE, down 4.25 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%